Efficacy and Tolerability of Controlled-Release and Immediate-Release Paroxetine in the Treatment of Depression

Rate of social anxiety disorder, its comorbidity with depression and paroxetine effects in outpatients in Japan

“…This rate was similar to the previous report (around 60% for completion of the study) [17,18]. The high rate of dropout might be due to adverse reactions such as nausea, abnormal ejaculation, somnolence, and dizziness occurring at 15% [19]. There may exist unknown reasons for the dropout, which are important for poor clinical outcomes.…”

The impact of medication regimen factors on adherence to chronic treatment: a review of literature

“…Generally, extended-release forms of these medications are similar in safety and efficacy, with mixed results on side effects. While venlafaxine has no tolerability advantage according to its package insert, the controlled-release form of paroxetine has lower rates of nausea than the immediate-release form (Golden et al 2002). Burke and McArthur-Miller (2001) demonstrated that weekly dosing of fluoxetine was comparable to daily dosing for the continuation of treatment of depression.…”

Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings

“…Paroxetine CR appears to be associated with decreased gastrointestinal side effects in depressed individuals (Golden et al 2002) and increased adherence relative to the immediate-release formulation in studies of anxious individuals (Keene et al 2005). Paroxetine CR has previously demonstrated efficacy in panic disorder (Sheehan et al 2005) and social anxiety disorder (Lepola et al 2004); this represents the first report of its use in GAD.…”